Neeraj Agarwal

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Concurrent tissue and circulating tumor DNA analysis in renal cell carcinoma: insights from a multimodal database

  The Oncologist · 2026-04-01

• Laparoscopic adrenalectomy: Preoperative data, surgical technique and clinical outcomes profile: A retrospective & prospective study at a tertiary care centre

  Urologia Journal · 2025-11-04

• Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet Oncology · 2025-10-28 · 3 citations

• Comment on “Efficacy of deep brain stimulation for obsessive-compulsive disorder: Umbrella review and updated meta-analysis”

  Psychiatry Research · 2025-10-28

• Barriers and Facilitators of Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer

  JAMA Network Open · 2025-10-09 · 1 citations

• Receipt of PARP Inhibitors in Patients With Metastatic Prostate Cancer Harboring <i>BRCA1/2</i> Alterations

  JAMA Network Open · 2025-10-02 · 1 citations

• Innovations in the Production of Multivitamins in Microbial Factories

  2025-07-25

• Silent but Invasive: A Case Report of a Sarcomatoid Bladder Carcinoma in a 29-Year-Old Male Presenting As Vesico-Cutaneous Fistula Without Hematuria

  Cureus · 2025-07-18

• International Society of Urological Pathology Consensus on Cancer Precursor Lesions. Working Group 1

  The American Journal of Surgical Pathology · 2025-06-23 · 12 citations

• A Foundation Model for Spatial ProteomicsPreprint

  ArXiv.org · 2025-06-03 · 4 citations

• Assessment of time-to-treatment-failure (TTF) as a surrogate endpoint for overall survival (OS) to immune checkpoint inhibitor (ICI) regimens in metastatic renal cell carcinoma (mRCC): Findings from an IMDC analysis.

  Journal of Clinical Oncology · 2025-05-28

• Mevrometostat in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone acetate: The phase 3, randomized MEVPRO-1 study.

  Journal of Clinical Oncology · 2025-05-28

• HIF family transcription factor expression in a cohort of 4362 patients with renal cell carcinoma (RCC).

  Journal of Clinical Oncology · 2025-05-28

• Androgen pathway gene expression and response to hormonal therapy in prostate cancer (SWOG S1216).

  Journal of Clinical Oncology · 2025-05-28

• A phase 3 study of 177Lu-rosptamab plus standard of care vs. standard of care alone in patients with metastatic castration-resistant prostate cancer (ProstACT Global).

  Journal of Clinical Oncology · 2025-05-28

• Race, Ethnicity, and Tumor Genomic Testing in Prostate Cancer

  JAMA Network Open · 2025-05-12 · 1 citations

• Abstract LB089: Exploring androgen receptor alterations (ARa) and their potential association with efficacy of first-line (1L) talazoparib (TALA) + enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): A post hoc analysis of TALAPRO-2

  Cancer Research · 2025-04-25

• Systemic treatment options for metastatic castration resistant prostate cancer: A living systematic reviewPreprint

  medRxiv · 2025-04-16

• MALIGNANT EPITHELIOID ANGIOMYOLIPOMA (EAML)/PECOMA OF THE KIDNEY: A COMPREHENSIVE GENOMIC PROFILING (CGP) STUDY

  Urologic Oncology Seminars and Original Investigations · 2025-02-27

• IN-DEPTH CHARACTERIZATION OF THE SAFETY PROFILE OF BELZUTIFAN MONOTHERAPY IN PATIENTS WITH RENAL CELL CARCINOMA: A POOLED ANALYSIS OF FOUR CLINICAL TRIALS

  Urologic Oncology Seminars and Original Investigations · 2025-02-27